Radiochemotherapy in small-cell lung cancer

Area of Science:

• Oncology
• Radiation Oncology
• Medical Thoracic Oncology

Background:

• Combined chemotherapy with thoracic radiotherapy and prophylactic cranial irradiation (PCI) is standard for limited-disease small-cell lung cancer (SCLC).
• Meta-analyses indicate these radiotherapy approaches improve 3-year survival by approximately 5%.
• Evidence suggests earlier thoracic radiotherapy initiation may benefit SCLC patients with good performance status.

Purpose of the Study:

• To evaluate the optimal total dose, fractionation, and irradiation volume for thoracic radiotherapy in limited-disease SCLC.
• To confirm the standard dose of 25 Gy in ten fractions for PCI in limited-disease SCLC.
• To investigate the role of consolidation thoracic radiotherapy in extensive-disease SCLC.

Main Methods:

• Ongoing Phase III randomized trials are assessing total dose for limited-disease SCLC.
• Recent data support the established PCI dose of 25 Gy/10 fractions for limited-disease SCLC.
• Prospective trials are evaluating the benefit of consolidation thoracic radiotherapy in extensive-disease SCLC.

Main Results:

• PCI in extensive-disease SCLC improves survival but negatively impacts short-term quality of life.
• The standard PCI dose of 25 Gy in ten fractions is confirmed for limited-disease SCLC.
• Evidence suggests potential value of consolidation thoracic radiotherapy in extensive-disease SCLC.

Conclusions:

• While established, optimal thoracic radiotherapy parameters for limited-disease SCLC require further investigation through ongoing trials.
• The current PCI regimen for limited-disease SCLC is validated, but its use in extensive-disease SCLC warrants careful consideration due to quality-of-life trade-offs.
• Consolidation thoracic radiotherapy may offer benefits in extensive-disease SCLC, pending results from prospective studies.